Experts in the management of breast cancer consider data updates presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting regarding metastatic HR-positive breast cancer.

Data from the following clinical trials is discussed:

PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with ER[+]/HER2[-] metastatic breast cancer. (Borrego, ASCO 2020 Abstract 1007)

Alpelisib + fulvestrant in patients with PIK3CA-mutated HR+/HER2– advanced breast cancer (ABC) previously treated with CDK 4/6 inhibitor + aromatase inhibitor: BYLieve study results.(Rugo, ASCO 2020 Abstract 1006)

Sara A. Hurvitz, MD, David Geffen School of Medicine

Articles

Metastatic HR+ Breast Cancer Updates